Compare · CGC vs NAGE
CGC vs NAGE
Side-by-side comparison of Canopy Growth Corporation (CGC) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 10.7x NAGE ($268.4M).
- Over the past year, CGC is down 35.6% and NAGE is down 74.8% - CGC leads by 39.2 points.
- CGC has been more active in the news (4 items in the past 4 weeks vs 2 for NAGE).
- CGC has more recent analyst coverage (19 ratings vs 1 for NAGE).
- Company
- Canopy Growth Corporation
- Niagen Bioscience Inc.
- Price
- $1.04+1.46%
- $3.40-1.16%
- Market cap
- $2.86B
- $268.4M
- 1M return
- -7.96%
- -19.24%
- 1Y return
- -35.60%
- -74.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 2
- Recent ratings
- 19
- 1
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CGC
- Canopy Growth Announces Claybourne's Frosted Flyers Wins 'Best Infused Pre-Roll' at 2026 Grow Up Awards
- SEC Form SD filed by Canopy Growth Corporation
- Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
- Canopy Growth Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Canopy Growth Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026
- Europe's Cannabis Boom Is Accelerating as Billions Flow into Licensed Markets
- Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
- 'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign
- SEC Form 4 filed by Yanofsky Theresa
Latest NAGE
- Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
- Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- Niagen Bioscience Announces Participation in Upcoming Investor Conferences
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
- SEC Form DEFA14A filed by Niagen Bioscience Inc.
- SEC Form DEF 14A filed by Niagen Bioscience Inc.
- Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™